Tivic Health Systems, Inc. - TIVC STOCK NEWS

Tivic Health® Systems, Inc. (Nasdaq: TIVC) announced its fourth quarter 2021 financial results and year-end shareholder update via conference call on April 19, 2022. The call is scheduled for 2:00 pm PT / 5:00 pm ET, providing insights into the company’s performance in the bioelectronic medicine sector. Interested participants can join by calling the toll-free number 888-506-0062 or the international number 973-528-0011 with the access code 689084. Tivic Health focuses on non-invasive treatments for inflammation and related conditions.

Tivic Health Systems (Nasdaq: TIVC) announced key executive appointments, effective April 1, 2022. Veronica Cai becomes Chief Financial Officer, succeeding Briana Benz. Ryan Sabia is promoted to Chief Operating Officer, and Sanjay Ahuja joins as Senior Vice President, Quality Assurance & Regulatory Affairs. Cai brings 25 years of finance experience, while Ahuja has over 25 years in regulatory affairs. CEO Jennifer Ernst emphasizes that their expertise aligns with the company's growth strategy in bioelectronic medicine.

Tivic Health (Nasdaq: TIVC), a healthtech company specializing in bioelectronic medicine, was featured in an ABC News story highlighting new bioelectronic technologies for managing conditions like sinus pain and arthritis. ClearUP® Sinus Pain Relief, the only commercially available product showcased, is part of the company's growth strategy following a $17.2 million IPO in November 2021. The company is advancing its Gen2 product and exploring new applications in bioelectronic therapies as alternatives to opioids.

Tivic Health Systems (Nasdaq: TIVC) has launched a 60-person clinical trial to investigate a new bioelectronic device as an alternative to opioids for post-operative care after sinus surgeries. This double-blind study aims to evaluate pain management following functional endoscopic sinus surgery, a common procedure affecting over one million patients annually in the U.S. The company currently offers an FDA-cleared treatment for sinus pain and nasal congestion, seeking to expand its application in pain reduction while minimizing opioid dependence.

Tivic Health Systems, Inc. (NASDAQ: TIVC), a company specializing in non-invasive bioelectronic medicine, has appointed Mindgruve as its digital marketing agency of record. Mindgruve will develop an integrated marketing strategy to enhance brand awareness and optimize e-commerce platforms for Tivic's products, including its FDA-cleared device, ClearUP® Sinus Pain Relief. This partnership aims to capitalize on the growing sinus care market and improve the effectiveness of Tivic's marketing and sales efforts in the U.S.

Tivic Health Systems, Inc. (NASDAQ: TIVC) has received significant recognition as CEO Jennifer Ernst was awarded Inc’s 2021 Female Founders 100 Award. Additionally, the company was listed in Fast Company’s inaugural Next Big Things in Tech 2021 for its FDA-cleared product, ClearUP® Sinus Pain Relief. This innovative device aims to alleviate nasal and sinus inflammation symptoms, marking a key milestone in the bioelectronic medicine sector. Ernst expressed pride in the team’s accomplishments and their mission to enhance healthcare delivery.

Tivic Health Systems, a commercial-phase bioelectronic medicine company, will present at the Sidoti Micro Cap Conference virtually on December 8, 2021, at 3:15 pm ET. CEO Jennifer Ernst will discuss bioelectronic medicine's growth and hold one-on-one investor meetings. Registration for the conference is mandatory, and more details can be found on Sidoti's website. Tivic Health is committed to advancing non-invasive health solutions to enhance wellness and improve lives.

Tivic Health Systems, Inc. (TIVC) announced the closing of its initial public offering, selling 3 million shares at $5.00 each, raising $15 million in gross proceeds. The offering includes a 45-day option for underwriters to purchase an additional 450,000 shares. The proceeds will be used to expand sales of its ClearUP® Sinus Relief device, enhance marketing efforts, and support the launch of ClearUP Gen 2. The company also aims to further clinical research and product development. ThinkEquity acted as the sole book-running manager for the offering.